Our Board
Dr. Örjan Andersson is the Founder of Bioxid Ltd, which founded DelSiTech Ltd (drug delivery), Stick Tech Oy (dental, exit 2012), and Vivoxid Oy (orthopedics, exit 2013). He has served as Chairman of Bioxid since 2007 and DelSiTech since 2010. Örjan was the inaugural Director of the Turku Biomaterials Center in the 1990s, playing a pioneering role in academia-industry collaboration. For his scientific achievements, he was honored with membership in the Swedish Academy of Engineering Sciences in Finland, recognizing his contributions to the field of biomaterials science. Örjan has served as Vice Chancellor of Novia University of Applied Sciences for more than 20 years and is an Adjunct Professor.
Education: Doctor of Science in Technology
Dr. Shawn Silvestri is the President and COO at Tomar, a role he has held since 2020. Previously, he was Global Head of R&D at Sandoz, a Division of Novartis, based in Holzkirchen, Bavaria, Germany, where he led numerous strategic initiatives. He served on the Sandoz Executive Committee and held various Board appointments. Before joining Sandoz, Shawn was the Corporate Vice President of R&D at Hospira, later acquired by Pfizer, where he played a key role in leading two major asset acquisitions, expanding the Development Organization, and overseeing a major restructuring and reinvestment project. Earlier in his career, Shawn worked at Abbott Laboratories in leadership roles across product development, manufacturing science, technology, and business development, specializing in Chemistry, Manufacturing, and Controls.
Education: PhD in Pharmaceutical Sciences, University of Connecticut; Executive Leadership, Harvard University
Dr. Jouni Heikkilä is an accomplished orthopedic surgeon and traumatologist with over 30 years of experience in biomaterials research. He is a co-founder of DelSiTech Ltd. and serves as CEO and Chairman of the Board for Ortopedipalvelu JAJ Oy, a major shareholder of DelSiTech. Jouni previously served as CEO of Bioxid Ltd, which played a key role in the founding of DelSiTech, Stick Tech, and Vivoxid. Heikkilä has held board positions in several biomedical companies and works as a specialist in a private hospital. His research interests include the use of bioactive glass in orthopedics and sports traumatology. He is also an Adjunct Professor at the University of Turku and has participated in humanitarian work at the ICRC Hospital for War Wounded in Kabul, Afghanistan.
Education: MD, PhD, University of Turku
Dr. Reijo Salonen has over 30 years of experience in drug development and commercialization in global pharmaceutical companies. A specialist in neurology and neuroimmunology, he was Senior Vice President, Head of R&D, and Chief Medical Officer at Orion Pharma, where he was a member of the Executive Management Team for more than a decade. He also held senior leadership roles at GSK, serving as Vice President and Global Head of Clinical Development in Neurosciences, and at Pfizer, where he was the Worldwide Therapeutic Area Head, leading worldwide medical and global development in neurosciences. His work spans across both strategic management and clinical development. Reijo is an Adjunct Professor and a Visiting Professor of InFLAMES Flagship Program at the University of Turku. He has also been awarded the honorary title of Professor honoris causa by the President of Finland.
Education: MD, PhD, University of Turku
Mr. Gunnar Björkstén is the Founder and President of the Sofinn Group of companies, with extensive experience in the pharmaceutical, biotech, and high-tech industries. His leadership and business acumen have been critical in establishing his companies as key players in their sectors.
Education: MSc (Econ)
Mr. Lewis Feldberg is a seasoned pharmaceutical executive with over 30 years of experience. He began his career at Merck before moving to Teva Pharmaceuticals, where he served as Vice President of Business Development – Europe. In 2007, he became CEO of Esteve USA, leading the establishment of the company’s U.S. operations. In 2012, he joined DRW to develop its biotech investment strategy. Since 2019, Lewis has been the Founder and CEO of Sophrosyne Pharmaceuticals, a company focused on addressing the drug and alcohol addiction crisis.
Education: MBA, Columbia Business School